Supplementary Material

Supplementary Table 1. Patient characteristics (variables not reported in Table 1).

Predictor	Deriv.	Valid.	Test, f.	Test, I.	Predictor	Deriv.	Valid.	Test, f.	Test, I.
Total patients					Missing	48 (4%)	23 (4%)	19 (3%)	5 (2%)
	1297	649	682	219	Aortic stenos				
Time to critic				40 (000()	Yes	43 (3%)	18 (3%)	14 (2%)	4 (2%)
1	75 (6%)	, ,	127 (19%)	48 (22%)	No Missing	1195 (92%)	, ,		210 (96%)
2	82 (6%)	31 (5%)	41 (6%)	` ,	Missing	59 (5%)	31 (5%)	20 (3%)	5 (2%)
4	89 (7%) 82 (6%)	26 (4%) 39 (6%)	38 (6%) 34 (5%)	16 (7%) 7 (3%)	AV block Yes	36 (3%)	16 (2%)	11 (2%)	2 (1%)
5	84 (6%)	39 (6%)	44 (6%)	12 (5%)	No	1201 (93%)		652 (96%)	` ,
6	84 (6%)	48 (7%)	34 (5%)	13 (6%)	Missing	60 (5%)	30 (5%)	19 (3%)	5 (2%)
7	87 (7%)	39 (6%)	42 (6%)	14 (6%)	Carotid arter	` ,	00 (070)	10 (070)	0 (270)
≥8		387 (60%)			Yes	37 (3%)	18 (3%)	12 (2%)	3 (1%)
Day of sympt	,	, ,	, ,	,	No	1184 (91%)	, ,	648 (95%)	` ,
to diagnosis)		•	•		Missing	76 (6%)	37 (6%)	22 (3%)	5 (2%)
≤ -8	188 (14%)	91 (14%)	76 (11%)	24 (11%)	Chronic hear	t failure			
-7	68 (5%)	47 (7%)	55 (8%)	22 (10%)	Yes	132 (10%)	75 (12%)	40 (6%)	14 (6%)
-6	38 (3%)	22 (3%)	22 (3%)	11 (5%)	No	1116 (86%)	, ,	` ,	
-5	60 (5%)	22 (3%)	27 (4%)	9 (4%)	Missing	49 (4%)	24 (4%)	19 (3%)	4 (2%)
-4	59 (5%)	14 (2%)	29 (4%)	9 (4%)	Peripheral va			00 (00()	7 (00()
-3	71 (5%)	41 (6%)	41 (6%)	14 (6%)	Yes	59 (5%)	29 (4%)	22 (3%)	7 (3%)
-2	85 (7%)	37 (6%)	50 (7%)	` ,	No Missing	1182 (91%)	, ,	20 (3%)	` ,
-1 0	88 (7%) 367 (28%)	49 (8%) 179 (28%)	49 (7%)	18 (8%) 58 (26%)	Missing Hypertensio i	56 (4%)	31 (5%)	20 (3%)	5 (2%)
o ≥ 1	82 (6%)	40 (6%)	10 (1%)	36 (26 %)	Yes	640 (49%)	310 (48%)	306 (45%)	88 (40%)
Missing	` ,	107 (16%)		34 (16%)	No	, ,	331 (51%)		` ,
Emergency h	, ,	, ,	101 (1070)	04 (1070)	Missing	19 (1%)	8 (1%)	11 (2%)	3 (1%)
Yes	•	245 (38%)	447 (66%)	131 (60%)	Atrial fibrillat	` ,	0 (170)	(270)	0 (170)
No		220 (34%)		84 (38%)	Yes	179 (14%)	97 (15%)	78 (11%)	17 (8%)
Missing	364 (28%)	, ,	12 (2%)	4 (2%)	No	1083 (84%)	530 (82%)	585 (86%)	198 (90%)
Month of diag	gnosis	, ,	, ,	` ,	Missing	35 (3%)	22 (3%)	19 (3%)	4 (2%)
≤3/2020	653 (50%)		91 (13%)	20 (9%)	Coronary art	ery disease			
4/2020	495 (38%)	238 (37%)	114 (17%)	23 (11%)	Yes	190 (15%)	93 (14%)	87 (13%)	19 (9%)
5/2020	99 (8%)	49 (8%)	29 (4%)	9 (4%)	No	1051 (81%)	, ,	, ,	195 (89%)
6/2020	38 (3%)	23 (4%)	16 (2%)	, ,	Missing	56 (4%)	30 (5%)	20 (3%)	5 (2%)
7/2020	12 (1%)	6 (1%)	65 (10%)	37 (17%)	COPD	70 (00()	00 (00()	44 (00()	40 (00()
8/2020	0 (0%)	0 (0%)	77 (11%)	` ,	Yes	73 (6%)	36 (6%)	41 (6%)	13 (6%)
9/2020	0 (0%)	0 (0%)	85 (12%)	35 (16%)	No	1198 (92%)		622 (91%)	` ,
10/2020 11/2020	0 (0%) 0 (0%)	0 (0%) 0 (0%)	184 (27%) 21 (3%)	59 (27%) 8 (4%)	Missing Asthma	26 (2%)	14 (2%)	19 (3%)	6 (3%)
Any neurolog	, ,	, ,	21 (370)	0 (4 /0)	Yes	60 (5%)	29 (4%)	47 (7%)	19 (9%)
Yes	•	145 (22%)	133 (20%)	32 (15%)	No	1209 (93%)		616 (90%)	
No	774 (60%)	, ,	, ,	,	Missing	28 (2%)	14 (2%)	19 (3%)	6 (3%)
Missing	, ,	111 (17%)	15 (2%)	5 (2%)	Other chroni	` ,	` ,	.0 (0,0)	0 (070)
Hemiplegia	(- ()	(11)	. (,	- ()	Yes	55 (4%)	35 (5%)	25 (4%)	9 (4%)
Yes	31 (2%)	16 (2%)	8 (1%)	3 (1%)	No	1194 (92%)	587 (90%)	638 (94%)	204 (93%)
No	1235 (95%)	614 (95%)	655 (96%)	211 (96%)	Missing	48 (4%)	27 (4%)	19 (3%)	6 (3%)
Missing	31 (2%)	19 (3%)	19 (3%)	5 (2%)	Leukemia				
Dementia					Yes	23 (2%)	10 (2%)	5 (1%)	1 (0%)
Yes	112 (9%)	65 (10%)	53 (8%)	10 (5%)	No	1241 (96%)			
No	,	568 (88%)	, ,	, ,	Missing	33 (3%)	14 (2%)	20 (3%)	5 (2%)
Missing	32 (2%)	16 (2%)	16 (2%)	5 (2%)	Lymphoma	00 (00()	47 (00()	0 (40()	4 (00()
Cerebrovasci				16 (70/)	Yes	39 (3%)	17 (3%)	9 (1%)	1 (0%)
Yes	128 (10%)		60 (9%)	16 (7%)	No Missing	1226 (95%)	, ,	, ,	`
No Missing	30 (2%)	567 (87%) 19 (3%)	18 (3%)	` ,	Missing Solid tumor	32 (2%)	14 (2%)	20 (3%)	5 (2%)
Movement dis				3 (2 /0)	Yes	116 (9%)	60 (9%)	43 (6%)	13 (6%)
Dystonia, Ata			uiscuse,		No	1151 (89%)			
Yes	28 (2%)	12 (2%)	0 (0%)	0 (0%)	Missing	30 (2%)		21 (3%)	6 (3%)
No	1014 (78%)		0 (0%)	0 (0%)	Solid tumor,			(0,0)	0 (070)
Missing		126 (19%)			Yes	57 (4%)	21 (3%)	17 (2%)	4 (2%)
Other neurolo	ogical autoir	nmune dise	ases	,	No	1205 (93%)	611 (94%)	646 (95%)	210 (96%)
Yes	5 (0%)	3 (0%)	1 (0%)	1 (0%)	Missing	35 (3%)	17 (3%)	19 (3%)	5 (2%)
No	1220 (94%)	614 (95%)	662 (97%)	213 (97%)	Stem cell tra	nsplantation			
Missing	72 (6%)	32 (5%)	19 (3%)	5 (2%)	Yes	10 (1%)	7 (1%)	0 (0%)	0 (0%)
Other prior no	eurological				No	1253 (97%)		` ,	214 (98%)
Yes	72 (6%)	35 (5%)	31 (5%)	9 (4%)	Missing	34 (3%)	13 (2%)	19 (3%)	5 (2%)
No		485 (75%)		`	Connective t				
Missing	, ,	129 (20%)	19 (3%)	5 (2%)	Yes	15 (1%)	4 (1%)	5 (1%)	1 (0%)
Myocardial in					No	1250 (96%)			
Yes	80 (6%)	43 (7%)	36 (5%)	7 (3%)	Missing	32 (2%)	15 (2%)	18 (3%)	5 (2%)
No	1169 (90%)	583 (90%)	627 (92%)	207 (95%)	Peptic ulcer	disease			

Predictor	Deriv.	Valid.	Test, f.	Test, I.	Predictor	Deriv.	Valid.	Test, f.	Test, I.
Yes	39 (3%)	17 (3%)	5 (1%)	1 (0%)	Missing	290 (22%)	147 (23%)	67 (10%)	14 (6%)
No	1226 (95%)	616 (95%)	657 (96%)	213 (97%)	Palpitations (sympt.)	` ,	` ,	` ,
Missing	32 (2%)	16 (2%)	20 (3%)	5 (2%)	Not quoted	, ,	494 (76%)	, ,	176 (80%)
Chronic liver		40 (00()	0 (40()	0 (10()	Quoted	15 (1%)	10 (2%)	4 (1%)	2 (1%)
Yes	29 (2%)	13 (2%)	8 (1%)	3 (1%)	Missing	, ,	145 (22%)	144 (21%)	41 (19%)
No Missing	1236 (95%) 32 (2%)	14 (2%)	21 (3%)	5 (2%)	Diarrhea (sym Not quoted		461 (71%)	502 (74%)	170 (78%)
Missing Liver cirrhosi	` ,	14 (270)	21 (3%)	3 (2%)	Quoted	110 (8%)	49 (8%)	69 (10%)	23 (11%)
Yes	15 (1%)	5 (1%)	6 (1%)	1 (0%)	Missing	` ,	` ,	` ,	26 (12%)
No	1252 (97%)				Nausea/emes	` ,	100 (2170)	111 (1070)	20 (1270)
Missing	30 (2%)	15 (2%)	20 (3%)	5 (2%)	Not quoted		458 (71%)	501 (73%)	167 (76%)
Diabetes, no			,	,	Quoted	98 (8%)	53 (8%)	61 (9%)	18 (8%)
Yes	164 (13%)	81 (12%)	101 (15%)	39 (18%)	Missing	284 (22%)	138 (21%)	120 (18%)	34 (16%)
No	1106 (85%)	554 (85%)	564 (83%)	177 (81%)	Muscle aches	(sympt.)			
Missing	27 (2%)	. 14 (2%)	17 (2%)	3 (1%)	Not quoted	` ,	445 (69%)	` ,	151 (69%)
Diabetes, with			05 (50()	4 (00()	Quoted	124 (10%)	58 (9%)	77 (11%)	31 (14%)
Yes	90 (7%)	47 (7%)	35 (5%)	4 (2%)	Missing		146 (22%)	135 (20%)	37 (17%)
No Missing	1177 (91%) 30 (2%)	15 (2%)	21 (3%)	210 (96%) 5 (2%)	Muscle weakr Not quoted		.) 462 (71%)	151 (67%)	147 (67%)
Acute kidney	` ,	15 (2 /6)	21 (370)	3 (2 /0)	Quoted	109 (8%)	41 (6%)	90 (13%)	35 (16%)
Yes	59 (5%)	33 (5%)	26 (4%)	5 (2%)	Missing		146 (22%)	138 (20%)	37 (17%)
No	` ,	445 (69%)	, ,	` ,	Fever (sympt.	, ,	110 (2270)	100 (2070)	0. (1.70)
Missing	,	171 (26%)	6 (1%)	0 (0%)	Not quoted	,	287 (44%)	300 (44%)	101 (46%)
Chronic kidne	, ,	, ,	,	,	Quoted	461 (36%)	237 (37%)	326 (48%)	103 (47%)
Yes	206 (16%)	97 (15%)	77 (11%)	17 (8%)	Missing	256 (20%)	125 (19%)	56 (8%)	15 (7%)
No	1060 (82%)		, ,	197 (90%)	Delirium (sym				
Missing	31 (2%)	15 (2%)	18 (3%)	5 (2%)	Not quoted	, ,	493 (76%)	, ,	193 (88%)
On dialysis	00 (00()	40 (00)		0 (00()	Quoted	23 (2%)	10 (2%)	9 (1%)	3 (1%)
Yes	26 (2%)	18 (3%)	14 (2%)	6 (3%)	Missing	, ,	146 (22%)	126 (18%)	23 (11%)
No Missing	1241 (96%) 30 (2%)	14 (2%)	20 (3%)	208 (95%) 5 (2%)	Excessive tire Not quoted	` •	• '	450 (66%)	144 (66%)
Organ transp	` ,	14 (2 /0)	20 (370)	3 (2 /0)	Quoted	210 (16%)	` ,	120 (18%)	50 (23%)
Yes	26 (2%)	18 (3%)	10 (1%)	4 (2%)	Missing		141 (22%)		25 (11%)
No	1240 (96%)				Headache (sy	, ,	111 (2270)	112 (1070)	20 (1170)
Missing	31 (2%)	14 (2%)	19 (3%)	5 (2%)	Not quoted		458 (71%)	462 (68%)	157 (72%)
Rheumatic di	sease		, ,	. ,	Quoted	109 (8%)	48 (7%)	84 (12%)	25 (11%)
Yes	46 (4%)	22 (3%)	23 (3%)	5 (2%)	Missing		143 (22%)	136 (20%)	37 (17%)
No	1187 (92%)	` ,			Meningism (s				
Missing	64 (5%)	29 (4%)	18 (3%)	5 (2%)	Not quoted		501 (77%)		177 (81%)
Stage of hear	•	, .		475 (000/)	Quoted	5 (0%)	2 (0%)	0 (0%)	0 (0%)
None NYHA I	48 (4%)	376 (58%) 22 (3%)	9 (1%)	175 (80%) 3 (1%)	Missing Smelling diso	` ,	146 (22%)	144 (21%)	42 (19%)
NYHA II	35 (3%)	28 (4%)	18 (3%)	8 (4%)	Not quoted		486 (75%)	503 (74%)	172 (79%)
NYHA III	34 (3%)	17 (3%)	24 (4%)	7 (3%)	Quoted	43 (3%)	12 (2%)	26 (4%)	6 (3%)
NYHA IV	10 (1%)	5 (1%)	5 (1%)	2 (1%)	Missing		151 (23%)		41 (19%)
Missing	, ,	201 (31%)	, ,	24 (11%)	Tasting disor			, ,	, ,
Asymptomati	c (sympt.)	, ,	, ,	, ,	Not quoted		478 (74%)	480 (70%)	164 (75%)
Not quoted	,	444 (68%)	, ,	167 (76%)	Quoted	58 (4%)	20 (3%)	58 (9%)	14 (6%)
Quoted	147 (11%)	73 (11%)	77 (11%)	29 (13%)	Missing		151 (23%)	144 (21%)	41 (19%)
Missing		132 (20%)	102 (15%)	23 (11%)	Other neurolo			500 (770()	470 (700()
Runny nose (404 (740/)	E14 (7E0/)	177 (010/)	Not quoted		480 (74%)	, ,	173 (79%)
Not quoted Quoted	. `	481 (74%) 21 (3%)	30 (4%)	177 (81%) 5 (2%)	Quoted	56 (4%)	21 (3%) 148 (23%)	14 (2%)	6 (3%) 40 (18%)
Missing	34 (3%) 308 (24%)		138 (20%)	37 (17%)	Missing Red eye (sym	` ,	140 (2370)	143 (2170)	40 (1070)
Sore throat (s		147 (2070)	100 (2070)	07 (1770)	Not quoted	. ,	498 (77%)	533 (78%)	178 (81%)
Not quoted		471 (73%)	490 (72%)	170 (78%)	Quoted	9 (1%)	6 (1%)	0 (0%)	0 (0%)
Quoted	59 (5%)	34 (5%)	58 (9%)	14 (6%)	Missing	301 (23%)	145 (22%)	149 (22%)	41 (19%)
Missing	303 (23%)	144 (22%)	134 (20%)	35 (16%)	Pulse				
Dry cough (s	ympt.)				< 60 bpm	39 (3%)	16 (2%)	20 (3%)	7 (3%)
Not quoted	` ,	331 (51%)	, ,	116 (53%)	60 - 89 bpm	717 (55%)	359 (55%)	372 (55%)	124 (57%)
Quoted	` ,	190 (29%)	, ,	90 (41%)	90 - 119	000 (000()	400 (000()	005 (00%)	07 (040()
Missing		128 (20%)	69 (10%)	13 (6%)	bpm	366 (28%)	180 (28%)	` ,	67 (31%)
Productive co		.) 471 (73%)	508 (74%)	174 (79%)	> 119 bpm Missing	50 (4%) 125 (10%)	26 (4%) 68 (10%)	33 (5%) 52 (8%)	10 (5%) 11 (5%)
Quoted	68 (5%)	34 (5%)	60 (9%)	19 (9%)	SBP	123 (1070)	00 (1070)	32 (070)	11 (370)
Missing	` ,	144 (22%)	114 (17%)	26 (12%)	< 80 mmHg	5 (0%)	3 (0%)	4 (1%)	1 (0%)
Wheezing (sy	. ` '	(== /0)	(, 0)	_0 (,0)	80 - 99	0 (0,0)	0 (070)	. (.,0)	. (0,0)
Not quoted		498 (77%)	530 (78%)	178 (81%)	mmHg	41 (3%)	32 (5%)	20 (3%)	6 (3%)
Quoted	16 (1%)	3 (0%)	10 (1%)	4 (2%)	100 - 119	, ,	. ,	. ,	. ,
Missing	, ,	148 (23%)	142 (21%)	37 (17%)	mmHg	282 (22%)	142 (22%)	124 (18%)	37 (17%)
Dyspnoe (syr		050 (550)	0== /===:	400 (=55)	120 - 139	457 (0	000 (0:51)	055 (055)	00 //:-::
Not quoted Quoted		359 (55%) 143 (22%)		130 (59%)	mmHg	4/1 (36%)	223 (34%)	255 (37%)	89 (41%)
Quoteu	201 (22/0)	170 (22 /0)	200 (00 /0)	75 (34%)					

Predictor	Deriv.	Valid.	Test, f.	Test, I.	Predictor	Deriv.	Valid.	Test, f.	Test, I.
140 - 179					Missing	418 (32%)	207 (32%)	77 (11%)	6 (3%
mmHg	352 (27%)	168 (26%)	210 (31%)	72 (33%)	Smoking state	us			
> 179					1-10 pack				
mmHg	33 (3%)	17 (3%)	20 (3%)	4 (2%)	years	22 (2%)	5 (1%)	8 (1%)	3 (1%
Missing	113 (9%)	64 (10%)	49 (7%)	10 (5%)	11-20 pack				
BP					years	14 (1%)	8 (1%)	6 (1%)	2 (1%)
< 40 mmHg	3 (0%)	3 (0%)	0 (0%)	0 (0%)	>21 pack				
40 - 59					years	34 (3%)	13 (2%)	9 (1%)	2 (1%)
mmHg	118 (9%)	60 (9%)	36 (5%)	9 (4%)	Nonsmoker	468 (36%)	255 (39%)	222 (33%)	84 (38%)
60 - 89					Former				
mmHg	861 (66%)	441 (68%)	480 (70%)	162 (74%)	smoker	103 (8%)	57 (9%)	50 (7%)	13 (6%)
90 - 109					Smoker,				
mmHg	188 (14%)	71 (11%)	103 (15%)	32 (15%)	unknown				
> 109					pack years	21 (2%)	14 (2%)	24 (4%)	9 (4%)
mmHg	11 (1%)	7 (1%)	14 (2%)	6 (3%)	Missing	635 (49%)	297 (46%)	363 (53%)	106 (48%)
Missing	116 (9%)	67 (10%)	49 (7%)	10 (5%)	IgG-titer posit	ive			
02					Yes	675 (52%)		645 (95%)	192 (88%)
< 60%	10 (1%)	1 (0%)	2 (0%)	1 (0%)	No	608 (47%)	293 (45%)	0 (0%)	0 (0%)
60 - 69%	5 (0%)	2 (0%)	1 (0%)	0 (0%)	51	0 (0%)	0 (0%)	15 (2%)	12 (5%)
70 - 79%	14 (1%)	11 (2%)	2 (0%)	1 (0%)	Missing	14 (1%)	7 (1%)	22 (3%)	15 (7%)
80 - 89%	124 (10%)	72 (11%)	58 (9%)	16 (7%)	AST				
90 - 95%	487 (38%)	222 (34%)	238 (35%)	67 (31%)	< LLN	2 (0%)	5 (1%)	9 (1%)	1 (0%)
96 - 100%	, ,	257 (40%)	317 (46%)	, ,	Normal	` /	` /	` /	,
Missing	152 (12%)	84 (13%)	64 (9%)	16 (7%)	(LLN - ULN)	714 (55%)	336 (52%)	367 (54%)	139 (63%)
ody tempera	,	(- 1 - 1)	(, , ,	(,	> ULN ≤ 2x	()	(,	(,	
< 35.1 °C	3 (0%)	5 (1%)	0 (0%)	0 (0%)	ULN	283 (22%)	160 (25%)	133 (20%)	60 (27%)
35.1 - 37.3	- (-,-)	- (1,1)	- (-,-,	- (-,-)	> 2x ULN ≤		(==,,,	(==,,,	(/-/
°C	501 (39%)	233 (36%)	282 (41%)	96 (44%)	5x ULN	73 (6%)	46 (7%)	33 (5%)	12 (5%)
37.3 - 37.9	00. (0070)	_00 (00 /0)	(, . ,	00 (1170)	> 5x ULN ≤	(0,70)	(. , . ,	00 (070)	(0,70)
°C	232 (18%)	138 (21%)	139 (20%)	54 (25%)	10x ULN	8 (1%)	3 (0%)	3 (0%)	0 (0%)
38 - 38.9 °C		141 (22%)	147 (22%)	36 (16%)	Missing	217 (17%)		137 (20%)	7 (3%)
39 - 39.9 °C	106 (8%)	63 (10%)	54 (8%)	17 (8%)	ALT	211 (1170)	00 (1070)	101 (2070)	. (070)
> 39.9 °C	10 (1%)	15 (2%)	6 (1%)	1 (0%)	< LLN	7 (1%)	8 (1%)	9 (1%)	2 (1%)
Missing	135 (10%)	54 (8%)	54 (8%)	15 (7%)	Normal	7 (170)	0 (170)	3 (170)	2 (170)
espiratory ra	, ,	04 (070)	04 (070)	10 (1 /0)	(LLN - ULN)	859 (66%)	416 (64%)	470 (69%)	162 (74%)
< 16	199 (15%)	96 (15%)	110 (16%)	29 (13%)	> ULN ≤ 2x	000 (0070)	+10 (0+70)	470 (0070)	102 (1470)
16-21		214 (33%)	245 (36%)	85 (39%)	ULN	220 (17%)	108 (17%)	100 (15%)	38 (17%)
22-29	211 (16%)	91 (14%)	86 (13%)	18 (8%)	> 2x ULN ≤	220 (17 70)	100 (17 70)	100 (1370)	30 (17 70)
> 29	45 (3%)	29 (4%)	41 (6%)	11 (5%)	5x ULN	42 (3%)	34 (5%)	31 (5%)	10 (5%)
Missing		219 (34%)		76 (35%)	> 5x ULN ≤	42 (070)	04 (070)	01 (070)	10 (070)
MI	401 (0070)	210 (0470)	200 (2070)	70 (0070)	10x ULN	8 (1%)	6 (1%)	5 (1%)	1 (0%)
< 18.5 kg/m²	23 (2%)	17 (3%)	13 (2%)	3 (1%)	Missing	161 (12%)	77 (12%)	67 (10%)	6 (3%)
18.5 - 24.9	23 (270)	17 (370)	13 (2 /0)	3 (170)	Gamma-GT	101 (1270)	11 (12/0)	07 (1070)	0 (3 /0)
kg/m²	201 (23%)	152 (23%)	110 (170/.)	50 (23%)	Normal				
25 - 29.9	301 (23 /6)	132 (23 /0)	110 (17 /0)	30 (23 /6)	(LLN - ULN)	679 (52%)	340 (54%)	397 (57%)	136 (62%)
	200 (220/)	125 (210/)	150 (220/)	EE (2E0/)	(LLIN - OLIN) > ULN ≤ 2x	070 (32/8)	349 (34 /0)	307 (37 /8)	130 (02 /0)
kg/m²	200 (22%)	135 (21%)	159 (25%)	55 (25%)		222 (470/)	106 (100/)	100 (160/)	44 (400/
30 - 34,9	404 (00/)	70 (440/)	00 (440/)	40 (400/)	ULN	222 (17%)	126 (19%)	108 (16%)	41 (19%)
kg/m²	121 (9%)	70 (11%)	96 (14%)	42 (19%)	> 2x ULN ≤	106 (00/)	EG (00/)	A7 /70/\	OF (440/)
> 34,9 kg/m²	55 (4%)	23 (4%)	43 (6%)	15 (7%)	5x ULN	106 (8%)	56 (9%)	47 (7%)	25 (11%)
Missing		252 (39%)	253 (37%)	54 (25%)	> 5x ULN ≤	04 (00/)	0 (40/)	45 (00/)	0 (40)
CE-inhibitor		100 (400/)	147 (000/)	20 (400()	10x ULN	34 (3%)	8 (1%)	15 (2%)	3 (1%)
Yes	. ,	, ,	147 (22%)	39 (18%)	> 10x ULN	0 (0%)	0 (0%)	9 (1%)	1 (0%)
	` ,		507 (74%)		Missing	257 (20%)	110 (17%)	116 (17%)	13 (6%)
Missing	37 (3%)	17 (3%)	28 (4%)	11 (5%)	Bilirubine	7 (40/)	7 /40/	44 (00/)	0 (40)
T1-RB	0.4= /.4==-/	100 //==-	00 // :=/	00 (10=11	< LLN	7 (1%)	7 (1%)	14 (2%)	2 (1%)
Yes		108 (17%)	98 (14%)	29 (13%)	Normal				
	` ,	524 (81%)			(LLN - ULN)	928 (72%)	470 (72%)	516 (76%)	196 (89%)
Missing	55 (4%)	17 (3%)	40 (6%)	12 (5%)	> ULN ≤ 2x				
tatines					ULN	50 (4%)	31 (5%)	41 (6%)	12 (5%)
Yes		138 (21%)	, ,	34 (16%)	> 2x ULN ≤				
No		378 (58%)	512 (75%)	` ,	5x ULN	9 (1%)	4 (1%)	5 (1%)	0 (0%)
Missing	274 (21%)	133 (20%)	34 (5%)	11 (5%)	Missing	303 (23%)	137 (21%)	106 (16%)	9 (4%)
ouprofen					Lipase				
Yes	47 (4%)	28 (4%)	29 (4%)	5 (2%)	< LLN	5 (0%)	2 (0%)	12 (2%)	4 (2%
No	1129 (87%)	566 (87%)	586 (86%)	194 (89%)	Normal	,			•
Missing	121 (9%)	55 (8%)	67 (10%)	20 (9%)	(LLN - ULN)	463 (36%)	223 (34%)	342 (50%)	152 (69%
mmunosuppr	` ,	()	. ,	` ,	> ULN ≤ 2x	, ,,	, ,,	,	,
	131 (10%)	71 (11%)	51 (7%)	19 (9%)	ULN	96 (7%)	51 (8%)	49 (7%)	15 (7%
		515 (79%)			> 2x ULN ≤	(- /0)	- (-,3)	- (- /-)	. (. /0
Yes			/	(30,0)		4.4.4.04.			
Yes No	. ,		60 (9%)	6 (3%)	5x UI N	11 (1%)	13 (2%)	8 (1%)	1 (0%)
Yes No Missing	152 (12%)	63 (10%)	60 (9%)	6 (3%)	5x ULN Missina	11 (1%) 722 (56%)	13 (2%) 360 (55%)	8 (1%) 271 (40%)	1 (0%) 47 (21%)
Yes No	152 (12%)	63 (10%)	, ,	6 (3%) 0 (0%)	5x ULN Missing Troponine T		13 (2%) 360 (55%)		1 (0%) 47 (21%)

Predictor	Deriv.	Valid.	Test, f.	Test, I.
Normal				
(LLN - ULN) > $ULN \le 2x$, ,	221 (34%)	250 (37%)	126 (58%)
ULN > 2x ULN ≤	84 (6%)	43 (7%)	49 (7%)	24 (11%)
5x ULN > 5x ULN ≤	57 (4%)	28 (4%)	43 (6%)	16 (7%)
10x ULN > 10x ULN ≤	18 (1%)	12 (2%)	12 (2%)	1 (0%)
20x ULN	10 (1%)	7 (1%)	4 (1%)	2 (1%)
> 20x ULN Missing	3 (0%) 687 (53%)	4 (1%) 326 (50%)	6 (1%) 304 (45%)	1 (0%) 41 (19%)
Creatinine < LLN	15 (1%)	13 (2%)	32 (5%)	6 (3%)
Normal	` ,	` ,		` ,
(LLN - ULN) > ULN ≤ 2x	, ,	, ,	477 (70%)	, ,
ULN > 2x ULN ≤	257 (20%)	140 (22%)	122 (18%)	, ,
5x ULN > 5x ULN ≤	69 (5%)	28 (4%)	26 (4%)	4 (2%)
20x ULN Missing	12 (1%) 26 (2%)	10 (2%) 15 (2%)	12 (2%) 13 (2%)	7 (3%) 1 (0%)
Leukocytes < 1,000 /µL	6 (0%)	5 (1%)	3 (0%)	1 (0%)
1,000 - 3999	, ,		, ,	, ,
/µL 4,000 -	234 (18%)	116 (18%)	105 (15%)	35 (16%)
7,999 /µL 8,000 -	742 (57%)	365 (56%)	386 (57%)	132 (60%)
11,999 /µL 12,000 -	224 (17%)	113 (17%)	124 (18%)	38 (17%)
15,999 /µL 16,000 -	43 (3%)	27 (4%)	34 (5%)	8 (4%)
19,999 /µL ≥ 20,000 /µL	22 (2%) 15 (1%)	10 (2%) 10 (2%)	10 (1%) 14 (2%)	0 (0%) 4 (2%)
Missing	11 (1%)	3 (0%)	6 (1%)	1 (0%)
Platelets < 10,000 /μL	7 (1%)	2 (0%)	3 (0%)	1 (0%)
10,000 - 49,999 /µL	22 (2%)	9 (1%)	7 (1%)	4 (2%)
50,000 - 119,999 /µL	121 (9%)	64 (10%)	59 (9%)	18 (8%)
120,000 - 449,999 /µL	1084 (84%)	554 (85%)	579 (85%)	193 (88%)
450,000 - 799,000 /μL	29 (2%)	12 (2%)	15 (2%)	1 (0%)
Missing	34 (3%)	8 (1%)	19 (3%)	2 (1%)
Hemoglobin < 6 g/dL	6 (0%)	3 (0%)	0 (0%)	0 (0%)
6 - 7.9 g/dL	40 (3%)	26 (4%)	14 (2%)	4 (2%)
8 - 9.9 g/dL	115 (9%)	48 (7%)	40 (6%)	13 (6%)
10 - 11.9 g/dL	243 (19%)	109 (17%)	137 (20%)	37 (17%)
12 - 14.9 g/dL	677 (52%)	364 (56%)	375 (55%)	132 (60%)
g/dL ≥ 15 g/dL	197 (15%)	94 (14%)	107 (16%)	32 (15%)
Missing	19 (1%)	5 (1%)	9 (1%)	1 (0%)
Areas of cons			400 (000()	407 (500()
Not quoted	521 (40%)	278 (43%)	428 (63%)	127 (58%)
Quoted Missing	216 (17%) 560 (43%)	103 (16%) 268 (41%)	115 (17%) 139 (20%)	55 (25%) 37 (17%)
Crazy paving			.00 (20 /0)	0, (1,70)
Not quoted	656 (51%)	332 (51%)	513 (75%)	165 (75%)
Quoted	37 (3%)	29 (4%)	30 (4%)	17 (8%)
Missing	604 (47%)	288 (44%)	139 (20%)	37 (17%)
Ground glass	376 (29%)	208 (32%)	329 (48%)	70 (32%)
Not quoted Quoted	361 (28%)	173 (27%)	214 (31%)	112 (51%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
Interlobular s		ning (CT)	` ,	. ,
Not quoted Quoted	664 (51%) 29 (2%)	348 (54%) 13 (2%)	529 (78%) 14 (2%)	174 (79%) 8 (4%)

Predictor	Deriv.	Valid.	Test, f.	Test, I.
Missing	604 (47%)	288 (44%)	139 (20%)	37 (17%)
Nodulary lesi	ons (CT)			
Not quoted	707 (55%)	364 (56%)	521 (76%)	164 (75%)
Quoted	30 (2%)	17 (3%)	22 (3%)	18 (8%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
Pleural effusi	on (CT)		, ,	, ,
Not quoted	686 (53%)	354 (55%)	509 (75%)	170 (78%)
Quoted	51 (4%)	27 (4%)	34 (5%)	12 (5%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
Normal (CT)	` ,	` ,	` ,	, ,
Not quoted	679 (52%)	337 (52%)	487 (71%)	168 (77%)
Quoted	58 (4%)	44 (7%)	56 (8%)	14 (6%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
MDRO coloni	zation	, ,	, ,	, ,
Yes	55 (4%)	19 (3%)	16 (2%)	6 (3%)
No	748 (58%)	395 (61%)	0 (0%)	0 (0%)
Missing	494 (38%)	235 (36%)	666 (98%)	213 (97%)
				474.00

Abbreviations: ACE, angiotensin-converting-enzyme; AT1-RB, angiotensin II receptor type 1 antagonists; AV, atrioventricular; BMI, body mass index; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; CT, computed tomography; DBP, diastolic blood pressure; LLN, lower limit of normal; MDRO, multidrug-resistant organism; NYHA, New York Heart Association functional classification; SBP, systolic blood pressure; sO2, oxygen saturation (%); sympt., variable describes whether a COVID-19 symptom is present at diagnosis; TIA, transient ischemic attack; ULN, upper limit of normal.


Supplementary Table 2. Summary of the predictive performances of Random Survival Forest and Cox models in comparison to the five variable score.

			C-index (ii	mp. range)
Selection	Model	N pr.	Derivation	Validation
All pr.	RSF	105	0.78 (0.78-0.78)	0.78 (0.77-0.78)
	Cox ridge	105	0.83 (0.81-0.83)	0.77 (0.77-0.77)
RSF Boruta	RSF	24	0.79 (0.79-0.80)	0.77 (0.76-0.77)
	Cox ridge	24	0.82 (0.81-0.82)	0.77 (0.77-0.77)
RF Boruta	RSF	5	0.74 (0.73-0.75)	0.73 (0.72-0.74)
	Cox ridge	5	0.76 (0.76-0.76)	0.76 (0.76-0.77)
	Binomial ridge	5	0.76 (0.76-0.76)	0.76 (0.76-0.77)
	Score	5	0.76 (0.76-0.76)	0.76 (0.76-0.77)
	30016	5	95%CI, 0.73-0.79	95%CI, 0.73-0.80
	Validation on			0.80 (0.80-0.81)
	full test set			95%CI, 0.76-0.84
	Validation on			0.81 (0.81-0.81)
	limited test set			95%CI, 0.74-0.87


Initial derivation and validation analyses were performed on the respective datasets (n=1297 and 649, respectively) as summarized in Figure 2. As indicated, the final score was additionally independently validated on the full and the limited test sets (n=675 and 218, as described in Figure 2).

Indicated are the median values and the full range for the imputed datasets (in brackets). Harrell's C-indices were calculated using a time to event variable (as summarized in Supplementary Figure 1) in addition to the outcome. 95% confidence intervals (95%CI) were calculated for score predictions using bootstrapping with equal contributions of the imputed datasets.


Abbreviations: AUC, area under the receiver operating characteristic (ROC) curve; C-index, concordance index; imp., imputation; N pr., number of predictors in the model; pr., predictors; RSF, random survival forest.



Supplementary Figure 1. Summary of the selected variables in the RF Boruta (A) and RSF Boruta (B) approaches. Indicated are the medians and interquartile ranges of variable importance obtained during the respective run of Boruta selection. Abbreviations: sO2, blood oxygen saturation; LDH, lactate dehydrogenase; AF, atrial fibrillation; AKI, acute kidney injury; AVB, atrioventricular block; CKD, chronic kidney disease; BMI, body mass index; CV, cardiovascular.



Supplementary Figure 2. Absolute risks for an event within 7 days of diagnosis or for all events for the indicated validation/test datasets. Lines represent mean predicted risk by a model calibrated on the derivation dataset. Dots represent observed absolute risk in the respective cohorts. Ranges indicate CI 95%.



Supplementary Figure 3. Score calibration results for event risk within 7 days of diagnosis (left panels) or for all events (right panels). Predictions for the indicated datasets were calculated with models calibrated on the derivation dataset. Solid lines represent optimal calibration. Ranges indicate CI 95%.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	2
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was	2
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	2
		reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	2-3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of	3
		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	31
		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	n.a.
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	3 ¹ , T.1,
		effect modifiers. Give diagnostic criteria, if applicable	S.T.1
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	31
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	3
		describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	3-4
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	n.a.
		(c) Explain how missing data were addressed	4
		(d) If applicable, explain how loss to follow-up was addressed	4
		(\underline{e}) Describe any sensitivity analyses	F. 3
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	3,
		potentially eligible, examined for eligibility, confirmed eligible, included in the	F.2
		study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	3,
			F.2 F.2
D : /: 1 /	1 44	(c) Consider use of a flow diagram	T.1,
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	S.T.1
		and information on exposures and potential confounders	T.1,
		(b) Indicate number of participants with missing data for each variable of interest	S.T.1
		(c) Summarise follow-up time (eg, average and total amount)	S.T.1
Outcome data	15*	Report numbers of outcome events or summary measures over time	T.1

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	T.2, T.3, T.5
		(b) Report category boundaries when continuous variables were categorized	T. 1 S.T.1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	S.F.2
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	F. 3, S.F.3
Discussion			
Key results	18	Summarise key results with reference to study objectives	6-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8-9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	6-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	7-9
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	9

^{*}Give information separately for exposed and unexposed groups.

Abbreviations: F., figure; T., table; S., supplementary.

¹We additionally reference a previous publications from the LEOSS group which reports on the study design in further detail: Jakob et al., First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)". Infection 2020.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.